A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...

Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...

Several protesters were arrested Wednesday after U.S. Agency for International Development workers were told via a text ...

A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...

Gilead Sciences has announced the European Medicines Agency’s (EMA) validation for a parallel accelerated review of ...

Three bovine veterinarians had undetected H5N1 avian influenza infections despite no apparent contact with infected cows, ...

The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...

The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...

Missed KHOU 11+’s live Q&A on injectable PrEP? Watch on demand as experts discuss this HIV prevention breakthrough and answer ...

Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

The processor uses qubits that can be measured without error and are resistant to outside interference, which the company ...